# AstraZeneca’s Imfinzi approved in EU for new dosing

- Link: https://www.directorstalkinterviews.com/astrazenecas-imfinzi-approved-in-eu-for-new-dosing/412953187
- Published: 2021-01-15T07:20:36+00:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Imfinzi_ (durvalumab) has been approved in the European Union and the UK for an
additional dosing option, a 1,500mg fixed dose every four weeks, in locally advanced,
unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express 
PD-L1 on at least 1% of tumour cells and whose disease has not progressed following
platinum-based chemoradiation therapy (CRT).

Lung cancer is the leading cause of cancer death and 80-85% of patients with lung
cancer have NSCLC.^(1-3) Approximately one third of patients are diagnosed in the
Stage III setting and the majority of these have unresectable tumours and are treated
with curative intent.^(3-5)

This new dosing option is consistent with the approved _Imfinzi_ dosing in extensive-
stage small cell lung cancer (ES-SCLC) and is available to patients with locally
advanced, unresectable NSCLC weighing more than 30kg.

The approval by the European Commission was based on data from several _Imfinzi_
clinical trials. These include the PACIFIC Phase III trial which supported the two-
week, weight-based dosing of 10mg/kg already approved in locally advanced, unresectable
NSCLC, and the CASPIAN Phase III trial which used four-week, fixed dosing during
maintenance treatment in ES-SCLC.

The approval follows an accelerated assessment by the Committee for Medicinal Products
for Human Use (CHMP) of the European Medicines Agency, which recommended approval
in December 2020. This CHMP recommendation and approval also apply to the UK.

> **Luis Paz-Ares, MD, PhD, Chair, Medical Oncology Department, Hospital Universitario
> Doce de Octubre, Madrid, Spain and principal investigator in the CASPIAN Phase
> III trial, said**: “Less-frequent dosing is important for cancer patients, and
> may be particularly relevant right now for those suffering from lung cancer, who
> are especially vulnerable to complications from COVID-19. Patients with cancer
> should be able to focus on living their lives as much as possible and doctors 
> can now offer them a more convenient dosing option that could reduce medical visits
> by half and help avoid unnecessary risk of exposure to infection in the healthcare
> setting.”

_Imfinzi_ was also recently approved for unresectable Stage III NSCLC after CRT 
in the US for the four-week, fixed-dose regimen. _Imfinzi_ is approved in the curative-
intent setting of unresectable, Stage III (locally advanced) NSCLC after CRT in 
the EU, US, Japan, China and many other countries, based on the PACIFIC Phase III
trial. Additionally, it is approved in the EU, US, Japan and many other countries
around the world for the treatment of ES-SCLC based on the CASPIAN Phase III trial.

**_Imfinzi_** 

_Imfinzi_ (durvalumab) is a human monoclonal antibody that binds to PD-L1 and blocks
the interaction of PD-L1 with PD-1 and CD80, countering the tumour’s immune-evading
tactics and releasing the inhibition of immune responses.

_Imfinzi_ is also approved for previously treated patients with advanced bladder
cancer in the US and several other countries.

As part of a broad development programme, _Imfinzi_ is being tested as a monotherapy
and in combinations including with tremelimumab, an anti-CTLA4 monoclonal antibody
and potential new medicine, as a treatment for patients with NSCLC, SCLC, bladder
cancer, head and neck cancer, liver cancer, biliary tract cancer, oesophageal cancer,
gastric and gastroesophageal cancer, cervical cancer, ovarian cancer, endometrial
cancer and other solid tumours.

> **Dave Fredrickson, Executive Vice President, Oncology Business Unit at AstraZeneca,
> said:** “We are pleased to offer a four-week dosing option to lung cancer patients
> in Europe to meet an urgent need and help enable continuity of care during the
> pandemic. Cancer won’t wait, and it is our job to provide patients with treatment
> options that address the challenges the pandemic poses to their care.”

Share on:
